Edgar Filing: BAUM CHARLES M - Form 4

BAUM CHARLES M Form 4 February 25, 2019 FORM 4 The form 5 obligations <i>See</i> Instruction 1(b). Check this bax if no longer subject to Section 16. Form 4 or Form 5 obligations <i>See</i> Instruction 1(b). (Print or Type Response)											
1. Name and Address of Reporting Person <u>*</u> BAUM CHARLES M			2. Issuer Name and Ticker or Trading Symbol Mirati Therapeutics, Inc. [MRTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200			3. Date of Earliest Transaction(Month/Day/Year)02/21/2019					Director 10% Owner Officer (give title Other (specify below) below) President & CEO			
			4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tabl	e I - Non-D	Derivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		nsaction Date 2A. Deemed h/Day/Year) Execution Date, if any (Month/Day/Year)			4. Securi on(A) or Di (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common				Code V	Amount	(D)	Price \$	(Instr. 3 and 4)			
Stock	02/21/2019			М	79	А	\$ 24.99	62,497	D		
Common Stock	02/21/2019			М	2	A	\$ 5.4	62,499	D		
Common Stock	02/21/2019			М	3,542	A	\$ 21.51	66,041	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02) required to respond unless the form

1

Edgar Filing: BAUM CHARLES M - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8] (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 24.99	02/21/2019		М	79	(1)	01/21/2026	Common Stock	79	
Stock Option (Right to Buy)	\$ 5.4	02/21/2019		М	2	<u>(1)</u>	01/25/2027	Common Stock	2	
Stock Option (Right to Buy)	\$ 21.51	02/21/2019		М	3,542	<u>(1)</u>	02/03/2025	Common Stock	3,542	

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
BAUM CHARLES M C/O MIRATI THERAPEUTICS INC. 9393 TOWNE CENTRE DRIVE, STR SAN DIEGO, CA 92121			President & CEO					
Signatures								
/s/ Vickie Reed, Attorney-in-Fact	02/25/2019							

**Signature of Reporting Person

Date

8. I De Sec (In

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.